logo-loader
viewMaxCyte Inc

MaxCyte performs strongly in H1; CARMA Cell Therapies expected to be self-funding by year-end

Assessing the financial performance of the commercial operation, the company said current trading had been strong and the momentum had continued into the early part of the second half

MaxCyte Inc -

MaxCyte PLC (LON:MXCT) said its revenues grew by 30% to US$10.9mln in the first half of 2020 and told investors that its research and development operation was expected to be self-funded by the end of the year.

The company licences out its technology, which generates a revenue stream and potential milestone payment, currently worth an estimated US$800mln, from life sciences companies that use its cell engineering know-how in drug development.

It has also begun advancing its own potential treatments, creating an R&D business called CARMA Cell Therapies.

Scientists working for CARMA are currently developing a potential therapy for ovarian cancer and peritoneal mesothelioma. Results from a phase I study are expected later this year.

In the meantime, management has been working with a strategic advisory firm called Locust Walk on “the capital acquisition process”.

Following on from this, MaxCyte said it expects CARMA Cell Therapies to be self-funded by the end of 2020.

“The near-term prospects of independent funding for CARMA can highlight the value of this pioneering therapeutic platform,” said Emma Ulker, Proactive’s healthcare analyst.

She pointed out that the IPO pricing of the pre-clinical stage cell therapy company, Nkarta Therapeutics, indicated a market valuation of over £200mln, “illustrating the scope of interest in innovation in the therapeutic space”.

The shares, up 7% at 236p, values the entire business, including the revenue-generating operations and the potential clinical milestone payments at just £157mln.

Assessing the financial performance of the commercial operation, MaxCyte said current trading had been strong and the momentum had continued into the early part of the second half.

It is launching an expanded range of ExPERT disposables to “broaden applications by customers”, and presumably, enhance revenues.

A successful US$30mln financing in May has provided the financial support for MaxCyte’s planned dual listing on US Nasdaq growth market next year.

---adds analyst comment and share price---

Quick facts: MaxCyte Inc

Price: 338 GBX

AIM:MXCT
Market: AIM
Market Cap: £260.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc 'demonstrating outstanding progress' as first half revenues...

Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid...

4 weeks, 1 day ago

2 min read